Amy Errett Joins Pendulum Therapeutics Board to Scale Microbiome Health

Errett brings decades of experience as a four-time entrepreneur and former general partner at venture firm Maveron. Her track record at Madison Reed, where she built an omnichannel beauty empire, will serve as a blueprint for Pendulum’s next phase of growth. CEO Colleen Cutcliffe noted that Errett’s ability to challenge market status quos will be instrumental as the company scales its reach into metabolic and women’s health.

Pendulum has staked its reputation on rigorous clinical validation, most notably with its Pendulum Glucose Control probiotic, which demonstrated an ability to reduce A1C levels in Type 2 diabetes patients in a 2020 BMJ study. The company is now diversifying its product line, recently introducing Gut Fuel, a fiber supplement designed for broader dietary integration. With backing from investors like Sequoia Capital and the Mayo Clinic, the board appointment aims to bridge the gap between complex microbial science and daily consumer wellness habits.